These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 843257)

  • 1. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
    Rivera-Calimlim L; Tandon D; Anderson F; Joynt R
    Arch Neurol; 1977 Apr; 34(4):228-32. PubMed ID: 843257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
    Sweet RD; McDowell FH; Wasterlain CG; Stern PH
    Arch Neurol; 1975 Aug; 32(8):560-3. PubMed ID: 1156214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
    Lieberman A; Goodgold A; Jonas S; Leibowitz M
    Neurology; 1975 Oct; 25(10):911-6. PubMed ID: 1101099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
    Saarinen A; Myllylä VV; Tokola O; Hokkanen E
    Acta Neurol Scand; 1978 Dec; 58(6):340-9. PubMed ID: 369277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Carbiodopa-levodopa therapy (Sinemet) in the treatment of parkinsonian patients. Results of 4 years of treatment].
    Martínez-Lage JM; Burguera JA; Deldago G; Zubieta JL
    Arch Neurobiol (Madr); 1978; 41(1):3-18. PubMed ID: 697513
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
    Glasgow GL; Henley JW; Willoughby EW
    Aust N Z J Med; 1974 Aug; 4(4):373-8. PubMed ID: 4278910
    [No Abstract]   [Full Text] [Related]  

  • 9. [The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients].
    Völler GW; Deze J
    ZFA (Stuttgart); 1976 Mar; 52(7):380-8. PubMed ID: 773025
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease.
    Wajsbort J; Dorner A; Wajsbort E
    Curr Med Res Opin; 1978; 5(9):695-708. PubMed ID: 367714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 13. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L; Meneghetti G; Rigotti S; Saia A
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
    Feuerstein C; Tanche M; Serre F; Gavend M; Pellat J; Perret J
    Acta Neurol Scand; 1977 Jul; 56(1):79-82. PubMed ID: 878846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L; De la Garza R
    Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
    Contin M; Riva R; Martinelli P; Procaccianti G; Baruzzi A
    Clin Neuropharmacol; 1989 Feb; 12(1):75-81. PubMed ID: 2713868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Carbidopa-levodopa, growth hormone and parkinsonism].
    Marti-Masso JF; Carrera N; Martínez-Lage JM
    Rev Clin Esp; 1976 Jun; 141(6):525-32. PubMed ID: 968087
    [No Abstract]   [Full Text] [Related]  

  • 19. Psychiatric symptoms with initiation of carbidopa-levodopa treatment.
    Lin JT; Ziegler DK
    Neurology; 1976 Jul; 26(7):699-700. PubMed ID: 945518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
    Feuerstein C; Serre F; Gavend M; Pellat J; Perret J; Tanche M
    Acta Neurol Scand; 1977 Dec; 56(6):508-24. PubMed ID: 605774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.